NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
The Nasdaq-listed company has booked a Type B End-of-Phase meeting to discuss accelerated approval for intranasal NEO100 in brain cancer, as its CEO added to his share purchases.
NeOnc Technologies (Nasdaq: NTHI) said on 16 November 2026 that it has a Type B End-of-Phase meeting with the US Food and Drug Administration scheduled for early January 2027. The agenda covers a possible accelerated approval pathway for NEO100, an intranasal treatment for brain cancer, and the design of a Phase 3 confirmatory trial.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗
Article written by VigiEye from the official source (Neonc Technologies Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.